RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > User Testing: The EMEA Experience

User Testing: The EMEA Experience

Posted 01 April 2008 | By

Introduced by the revised pharmaceutical legislation in November 2005, consulting target patient groups ("user testing") aims to improve the information provided in the package leaflet (PL) and make it more suitable to patients' and caregivers' needs. EMEA analysed the first year of experience with user testing by reviewing report assessments submitted by the pharmaceutical industry to identify areas where different views have been expressed. These results were shared and discussed with the Coordination Group for Mutual Recognition and Decentralised Procedures-Human (CMD(h)) with the objective of harmonising the approach to user testing at the European level. Preliminary results regarding compliance and final outcome are encouraging. However, one of the main conclusions of the exercise is the need for further guidance for both industry and assessors.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe